

Didier Samuel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2146212/publications.pdf>

Version: 2024-02-01

544
papers

30,791
citations

3731

89
h-index

6131

159
g-index

572
all docs

572
docs citations

572
times ranked

19400
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver Transplantation in European Patients with the Hepatitis B Surface Antigen. <i>New England Journal of Medicine</i> , 1993, 329, 1842-1847.	27.0	1,015
2	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. <i>Hepatology International</i> , 2014, 8, 453-471.	4.2	861
3	Early Liver Transplantation for Severe Alcoholic Hepatitis. <i>New England Journal of Medicine</i> , 2011, 365, 1790-1800.	27.0	792
4	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	3.7	741
5	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). <i>Hepatology International</i> , 2009, 3, 269-282.	4.2	709
6	Clinical and histological follow-up after liver transplantation (LT) for hereditary hemochromatosis (HH). <i>Journal of Hepatology</i> , 2003, 38, 38.	3.7	707
7	EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. <i>Journal of Hepatology</i> , 2017, 66, 1047-1081.	3.7	601
8	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. <i>Lancet, The</i> , 2019, 393, 1453-1464.	13.7	449
9	Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. <i>Gastroenterology</i> , 2002, 122, 923-930.	1.3	429
10	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) â€“ NCT01514890. <i>Journal of Hepatology</i> , 2013, 59, 434-441.	3.7	407
11	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 685-697.	9.1	402
12	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. <i>Journal of Hepatology</i> , 2018, 68, 1181-1190.	3.7	372
13	European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. <i>Gastroenterology</i> , 1999, 117, 619-625.	1.3	345
14	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 71, 397-408.	3.7	341
15	Interferon-Î± 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. <i>Gastroenterology</i> , 2003, 124, 642-650.	1.3	331
16	Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. <i>Gastroenterology</i> , 2015, 148, 108-117.	1.3	317
17	Liver Resection as a Bridge to Transplantation for Hepatocellular Carcinoma on Cirrhosis. <i>Annals of Surgery</i> , 2003, 238, 508-519.	4.2	306
18	Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. <i>Gastroenterology</i> , 1995, 108, 1088-1096.	1.3	296

#	ARTICLE	IF	CITATIONS
19	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840.	3.7	289
20	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
21	Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3. <i>Journal of Hepatology</i> , 2017, 67, 708-715.	3.7	276
22	Orthotopic Liver Transplantation in Fulminant and Subfulminant Hepatitis The Paul Brousse Experience. <i>Annals of Surgery</i> , 1995, 222, 109-119.	4.2	275
23	Liver Transplantation for Hereditary Transthyretin Amyloidosis. <i>Transplantation</i> , 2015, 99, 1847-1854.	1.0	257
24	Delayed Introduction of Reduced-Dose Tacrolimus, and Renal Function in Liver Transplantation: The "ReSpECT"™ Study. <i>American Journal of Transplantation</i> , 2009, 9, 327-336.	4.7	250
25	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. <i>Liver Transplantation</i> , 2007, 13, 349-360.	2.4	239
26	Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. <i>Gastroenterology</i> , 1993, 104, 549-555.	1.3	236
27	The course of hepatitis C virus infection after liver transplantation. <i>Hepatology</i> , 1994, 20, 1137-1143.	7.3	236
28	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 132-142.e4.	1.3	232
29	Albumin Dialysis With a Noncell Artificial Liver Support Device in Patients With Acute Liver Failure. <i>Annals of Internal Medicine</i> , 2013, 159, 522.	3.9	231
30	Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. <i>Liver Transplantation</i> , 2007, 13, 996-1003.	2.4	229
31	The course of hepatitis C virus infection after liver transplantation*1. <i>Hepatology</i> , 1994, 20, 1137-1143.	7.3	227
32	An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. <i>Hepatology</i> , 1995, 22, 1084-1089.	7.3	226
33	Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review. <i>Hepatology</i> , 2000, 32, 1189-1195.	7.3	224
34	Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, S1-S56.	1.0	217
35	Progression of Alpha-fetoprotein Before Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients: A Critical Factor. <i>American Journal of Transplantation</i> , 2010, 10, 129-137.	4.7	213
36	HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. <i>Hepatology</i> , 2003, 38, 86-95.	7.3	212

#	ARTICLE	IF	CITATIONS
37	Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. <i>Journal of Hepatology</i> , 2018, 69, 810-817.	3.7	199
38	Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. <i>Hepatology</i> , 2003, 38, 1419-1427.	7.3	190
39	Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. <i>Journal of Hepatology</i> , 1999, 30, 131-141.	3.7	186
40	Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. <i>Journal of Hepatology</i> , 2014, 60, 78-86.	3.7	182
41	Survival and recurrence of hepatitis C after liver transplantation in patients coinfecting with human immunodeficiency virus and hepatitis C virus. <i>Hepatology</i> , 2008, 47, 407-417.	7.3	178
42	A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. <i>Gut</i> , 2003, 52, 893-897.	12.1	177
43	Viral and clinical factors associated with the fulminant course of hepatitis A infection. <i>Hepatology</i> , 2003, 38, 613-618.	7.3	176
44	Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an Intensive Care Unit. <i>Journal of Hepatology</i> , 2012, 56, 95-102.	3.7	172
45	Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2001, 35, 590-597.	3.7	170
46	PERSISTENT HEPATITIS B VIRUS INFECTION OF MONONUCLEAR BLOOD CELLS WITHOUT CONCOMITANT LIVER INFECTION. <i>Transplantation</i> , 1990, 49, 1155-1157.	1.0	168
47	Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. <i>Liver Transplantation</i> , 2005, 11, 716-732.	2.4	168
48	Decision for Retransplantation of the Liver. <i>Annals of Surgery</i> , 2002, 236, 713-721.	4.2	167
49	Transfer of Symptomatic Peanut Allergy to the Recipient of a Combined Liver-And-Kidney Transplant. <i>New England Journal of Medicine</i> , 1997, 337, 822-825.	27.0	166
50	Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2020, 72, 965-981.	7.3	159
51	Etiology and prognosis of fulminant hepatitis in adults. <i>Liver Transplantation</i> , 2008, 14, S67-S79.	2.4	157
52	Hepatocellular Carcinoma Is Associated With an Increased Risk of Hepatitis B Virus Recurrence After Liver Transplantation. <i>Gastroenterology</i> , 2008, 134, 1890-1899.	1.3	155
53	Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. <i>Hepatology</i> , 1995, 21, 333-339.	7.3	152
54	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149

#	ARTICLE	IF	CITATIONS
55	De novo and apparent de novo hepatitis B virus infection after liver transplantation. <i>Journal of Hepatology</i> , 1997, 26, 517-526.	3.7	144
56	Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. <i>Journal of Hepatology</i> , 2003, 39, 587-594.	3.7	142
57	Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. <i>Transplantation</i> , 2003, 76, 1699-1704.	1.0	141
58	HRas Signal Transduction Promotes Hepatitis C Virus Cell Entry by Triggering Assembly of the Host Tetraspanin Receptor Complex. <i>Cell Host and Microbe</i> , 2013, 13, 302-313.	11.0	141
59	From immunosuppression to tolerance. <i>Journal of Hepatology</i> , 2015, 62, S170-S185.	3.7	133
60	Compartmentalization of Hepatitis C Virus Genotypes between Plasma and Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 2005, 79, 6349-6357.	3.4	132
61	A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation. <i>Liver Transplantation</i> , 2017, 23, 143-154.	2.4	132
62	Liver Transplantation in Europe for Patients with Acute Liver Failure. <i>Seminars in Liver Disease</i> , 1996, 16, 415-425.	3.6	130
63	Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. <i>Liver Transplantation</i> , 2006, 12, 1640-1648.	2.4	129
64	Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. <i>Liver Transplantation</i> , 2008, 14, 1766-1777.	2.4	129
65	Outcome of patients with cirrhosis requiring mechanical ventilation in ICU. <i>Journal of Hepatology</i> , 2014, 60, 570-578.	3.7	129
66	THE USE OF ABO-INCOMPATIBLE GRAFTS IN LIVER TRANSPLANTATION. <i>Transplantation</i> , 1995, 59, 1124-1132.	1.0	128
67	RESULTS OF LIS2T, A MULTICENTER, RANDOMIZED STUDY COMPARING CYCLOSPORINE MICROEMULSION WITH C2 MONITORING AND TACROLIMUS WITH C0 MONITORING IN DE NOVO LIVER TRANSPLANTATION. <i>Transplantation</i> , 2004, 77, 1632-1638.	1.0	124
68	All liver recipients benefit from the protocol 10-year liver biopsies. <i>Hepatology</i> , 2003, 37, 1293-1301.	7.3	119
69	Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. <i>Journal of the American College of Surgeons</i> , 1999, 189, 584-593.	0.5	116
70	Herpes simplex virus-associated acute liver failure: A difficult diagnosis with a poor prognosis. <i>Liver Transplantation</i> , 2005, 11, 1550-1555.	2.4	111
71	Liver Cancer-Derived Hepatitis C Virus Core Proteins Shift TGF-Beta Responses from Tumor Suppression to Epithelial-Mesenchymal Transition. <i>PLoS ONE</i> , 2009, 4, e4355.	2.5	110
72	Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. <i>Gut</i> , 2002, 50, 95-99.	12.1	109

#	ARTICLE	IF	CITATIONS
73	The impact of treatment of hepatitis C with <scp>DAA</scp>s on the occurrence of <scp>HCC</scp>. Liver International, 2018, 38, 139-145.	3.9	109
74	Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Journal of Hepatology, 1999, 30, 1130-1137.	3.7	107
75	Enteric Delivery of Regenerating Family Member 3 alpha Alters the Intestinal Microbiota and Controls Inflammation in Mice With Colitis. Gastroenterology, 2018, 154, 1009-1023.e14.	1.3	107
76	Incidence of Renal and Liver Rejection and Patient Survival Rate Following Combined Liver and Kidney Transplantation. American Journal of Transplantation, 2003, 3, 348-356.	4.7	106
77	Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology, 2016, 64, 1049-1056.	7.3	106
78	Nonrandom Distribution of Hepatitis C Virus Quasispecies in Plasma and Peripheral Blood Mononuclear Cell Subsets. Journal of Virology, 1999, 73, 9213-9221.	3.4	105
79	Long term results of liver transplantation for Wilson's disease: Experience in France. Journal of Hepatology, 2014, 60, 579-589.	3.7	103
80	Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?. Journal of Hepatology, 2015, 63, 83-92.	3.7	101
81	Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. Journal of Hepatology, 1997, 26, 228-235.	3.7	100
82	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. Journal of Hepatology, 2017, 66, 39-47.	3.7	100
83	Silent presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. Hepatology, 1999, 30, 1144-1150.	7.3	99
84	Telbivudine Improves Renal Function in Patients With Chronic Hepatitis B. Gastroenterology, 2014, 146, 138-146.e5.	1.3	99
85	Personalized Adapted Physical Activity Before Liver Transplantation. Transplantation, 2015, 99, 145-150.	1.0	98
86	Characteristics of patients with chronic hepatitis B in France: Predominant frequency of HBe antigen negative cases. Journal of Hepatology, 2006, 45, 355-360.	3.7	96
87	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). Journal of Hepatology, 2021, 75, 610-622.	3.7	96
88	Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology, 1997, 26, 1343-1350.	7.3	95
89	Auxiliary Partial Orthotopic Versus Standard Orthotopic Whole Liver Transplantation for Acute Liver Failure. Annals of Surgery, 2001, 234, 723-731.	4.2	94
90	Prognostic Value of Quantitative Kaposi Sarcoma-associated Herpesvirus Load in Posttransplantation Kaposi Sarcoma. Journal of Infectious Diseases, 2002, 186, 110-113.	4.0	93

#	ARTICLE	IF	CITATIONS
91	12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. <i>Liver Transplantation</i> , 2006, 12, 1464-1472.	2.4	92
92	ATP release after partial hepatectomy regulates liver regeneration in the rat. <i>Journal of Hepatology</i> , 2010, 52, 54-62.	3.7	91
93	Risk factors for hepatitis C recurrence after liver transplantation. <i>Journal of Viral Hepatitis</i> , 2007, 14, 89-96.	2.0	89
94	Auxiliary Partial Orthotopic Liver Transplantation for Fulminant Hepatitis. <i>Annals of Surgery</i> , 1996, 224, 712-726.	4.2	89
95	Short- and Long-term Donor Morbidity in Right Lobe Living Donor Liver Transplantation: 91 Consecutive Cases in a European Center. <i>American Journal of Transplantation</i> , 2011, 11, 101-110.	4.7	87
96	Clinical and Therapeutic Implications of Hepatitis C Virus Compartmentalization. <i>Gastroenterology</i> , 2006, 131, 76-84.	1.3	86
97	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. <i>JHEP Reports</i> , 2020, 2, 100170.	4.9	86
98	Longitudinal prospective evaluation of quality of life in adult patients before and one year after liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 703-711.	2.4	84
99	Evolving strategies to prevent HBV recurrence. <i>Liver Transplantation</i> , 2004, 10, S74-S85.	2.4	84
100	Fungal infections after liver transplantation: outcomes and risk factors revisited in the <sc>MELD</sc> era. <i>Clinical Transplantation</i> , 2013, 27, E454-61.	1.6	84
101	NEUROLOGICAL IMPROVEMENT DURING BIOARTIFICIAL LIVER SESSIONS IN PATIENTS WITH ACUTE LIVER FAILURE AWAITING TRANSPLANTATION1. <i>Transplantation</i> , 2002, 73, 257-264.	1.0	81
102	Portopulmonary hypertension in the current era of pulmonary hypertension management. <i>Journal of Hepatology</i> , 2020, 73, 130-139.	3.7	78
103	Sclerosing Cholangitis Following Human Orthotopic Liver Transplantation. <i>American Journal of Surgical Pathology</i> , 1995, 19, 81-90.	3.7	76
104	Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. <i>Digestive and Liver Disease</i> , 2009, 41, 350-356.	0.9	76
105	Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis. <i>Journal of Hepatology</i> , 2011, 54, 481-488.	3.7	76
106	Resection or Transplantation for Early Hepatocellular Carcinoma in a Cirrhotic Liver. <i>Annals of Surgery</i> , 2012, 256, 883-891.	4.2	76
107	Efficacy and safety of simeprevir with PegIFN/ribavirin in na ⁺ ve or experienced patients infected with chronic HCV genotype 4. <i>Journal of Hepatology</i> , 2015, 62, 1047-1055.	3.7	76
108	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , 2017, 101, 945-955.	1.0	76

#	ARTICLE	IF	CITATIONS
109	Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. <i>Hepatology</i> , 1995, 21, 929-932.	7.3	75
110	Liver transplantation in patients with HIV infection. <i>Journal of Hepatology</i> , 2003, 39, 3-6.	3.7	74
111	Liver transplantation for severe acute liver failure after herbal medicine. <i>Journal of Hepatology</i> , 1995, 22, 597.	3.7	72
112	Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – The ANRS CUIPILT study. <i>Journal of Hepatology</i> , 2016, 65, 711-718.	3.7	72
113	Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. <i>BMC Medicine</i> , 2018, 16, 113.	5.5	72
114	Pulmonary Complications After Elective Liver Transplantation – Incidence, Risk Factors, and Outcome. <i>Transplantation</i> , 2012, 94, 532-538.	1.0	71
115	Extreme Bradycardia After First Doses of Sofosbuvir and Daclatasvir in Patients Receiving Amiodarone: 2 Cases Including a Rechallenge. <i>Gastroenterology</i> , 2015, 149, 1378-1380.e1.	1.3	71
116	ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. <i>Journal of Hepatology</i> , 2017, 67, 585-602.	3.7	71
117	Plasma disappearance rate of indocyanine green: A tool to evaluate early graft outcome after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 1358-1364.	2.4	70
118	Cirrhotic patients in the ICU. <i>Current Opinion in Critical Care</i> , 2013, 19, 154-160.	3.2	70
119	Liver Transplantation for Protoporphyrin. <i>Gastroenterology</i> , 1988, 95, 816-819.	1.3	69
120	Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score-based liver allocation system. <i>Liver Transplantation</i> , 2011, 17, 1137-1151.	2.4	68
121	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. <i>Hepatology</i> , 2017, 65, 1683-1692.	7.3	68
122	G02 : Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trial. <i>Journal of Hepatology</i> , 2015, 62, S187-S188.	3.7	67
123	– EUROHEP™ consensus report on the management of liver transplantation for hepatitis B virus infection. <i>Journal of Hepatology</i> , 1994, 21, 1140-1143.	3.7	65
124	Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. <i>Liver Transplantation</i> , 2004, 10, 295-300.	2.4	65
125	Male cell microchimerism in normal and diseased female livers from fetal life to adulthood. <i>Hepatology</i> , 2005, 42, 35-43.	7.3	64
126	Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B – related end-stage liver disease. <i>Hepatology</i> , 1994, 19, 6-12.	7.3	63

#	ARTICLE	IF	CITATIONS
127	Hepatitis C virus treatment pre- and post-liver transplantation. <i>Liver International</i> , 2012, 32, 120-128.	3.9	62
128	HISTOLOGICAL FEATURES PREDICTIVE OF RECURRENCE OF PRIMARY BILIARY CIRRHOSIS AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 1998, 65, 1328-1333.	1.0	62
129	Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. <i>Kidney International</i> , 1998, 54, 1311-1319.	5.2	61
130	8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	3.7	61
131	Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis type B in France. <i>Journal of Hepatology</i> , 1993, 18, 119-122.	3.7	60
132	Management of Hepatitis B in Liver Transplantation Patients. <i>Seminars in Liver Disease</i> , 2004, 24, 55-62.	3.6	60
133	Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2004, 41, 446-453.	3.7	60
134	Decision for retransplantation of the liver: an experience- and cost-based analysis. <i>Annals of Surgery</i> , 2002, 236, 713-21; discussion 721.	4.2	60
135	Improved Survival in Liver Transplant Recipients Receiving Prolonged-Release Tacrolimus in the European Liver Transplant Registry. <i>American Journal of Transplantation</i> , 2015, 15, 1267-1282.	4.7	58
136	Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study. <i>Clinical Pharmacokinetics</i> , 2007, 46, 941-952.	3.5	56
137	Steroid withdrawal at day 14 after liver transplantation: A double-blind, placebo-controlled study. <i>Liver Transplantation</i> , 2004, 10, 1454-1460.	2.4	55
138	The difficulties of managing severe hepatitis B virus reactivation. <i>Liver International</i> , 2011, 31, 104-110.	3.9	55
139	Fibrosing Cholestatic Hepatitis in HIV/HCV Co-Infected Transplant Patients – Usefulness of Early Markers After Liver Transplantation. <i>American Journal of Transplantation</i> , 2011, 11, 1686-1695.	4.7	55
140	Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. <i>Liver Transplantation</i> , 2011, 17, S6-S13.	2.4	53
141	HCV core-mediated activation of latent TGF- β^2 via thrombospondin drives the crosstalk between hepatocytes and stromal environment. <i>Journal of Hepatology</i> , 2013, 59, 1160-1168.	3.7	53
142	Human Herpesvirus 8 (HHV8) Transmission and Related Morbidity in Organ Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 207-213.	4.7	53
143	Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: A randomized, open-label trial. <i>Liver Transplantation</i> , 2011, 17, 167-177.	2.4	51
144	Practical Management of Boceprevir and Immunosuppressive Therapy in Liver Transplant Recipients with Hepatitis C Virus Recurrence. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5728-5734.	3.2	51

#	ARTICLE	IF	CITATIONS
145	Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. <i>Liver Transplantation</i> , 2001, 7, 556-558.	2.4	50
146	Assessing Renal Function With Daclizumab Induction and Delayed Tacrolimus Introduction in Liver Transplant Recipients. <i>Transplantation</i> , 2010, 89, 1504-1510.	1.0	50
147	Current management and perspectives for <scp>HCV</scp> recurrence after liver transplantation. <i>Liver International</i> , 2013, 33, 56-62.	3.9	50
148	Should we screen blood products for hepatitis E virus RNA ?. <i>Lancet, The</i> , 2014, 383, 218.	13.7	50
149	Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation. <i>Transplantation</i> , 2015, 99, 1321-1334.	1.0	50
150	Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV–HCV co-infected patients. <i>Journal of Hepatology</i> , 2005, 42, 341-349.	3.7	49
151	Liver Transplantation in Delta Virus Infection. <i>Seminars in Liver Disease</i> , 2012, 32, 245-255.	3.6	49
152	Patients with acute liver failure listed for superurgent liver transplantation in France: Reevaluation of the clichy–villejuif criteria. <i>Liver Transplantation</i> , 2015, 21, 512-523.	2.4	49
153	Pros and Cons: Usage of organs from donors infected with hepatitis C virus – Revision in the direct-acting antiviral era. <i>Journal of Hepatology</i> , 2016, 64, 226-231.	3.7	49
154	Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. <i>Journal of Viral Hepatitis</i> , 2000, 7, 87-92.	2.0	48
155	Liver Retransplantation: A Model for Determining Long-Term Survival. <i>Transplantation</i> , 2006, 81, 1016-1021.	1.0	48
156	Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. <i>Journal of Hepatology</i> , 2012, 56, 840-847.	3.7	48
157	Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfecting patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. <i>Aids</i> , 2009, 23, 1069-1076.	2.2	47
158	Epidemiology of liver failure. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 610-617.	1.5	47
159	Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 1004-1010.	2.4	46
160	A new indication for liver transplantation: Nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. <i>Liver Transplantation</i> , 2008, 14, 1194-1198.	2.4	46
161	Liver transplantation for hepatocellular carcinoma: The impact of human immunodeficiency virus infection. <i>Hepatology</i> , 2011, 53, 475-482.	7.3	45
162	Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection. <i>Hepatology</i> , 2007, 46, 1704-1712.	7.3	44

#	ARTICLE	IF	CITATIONS
163	Are HIV-infected patients candidates for liver transplantation?. <i>Journal of Hepatology</i> , 2008, 48, 697-707.	3.7	44
164	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, 956-967.	1.0	44
165	Hepatitis B Virus Pregenomic RNA in Hepatocellular Carcinoma: A Nosological and Prognostic Determinant. <i>Hepatology</i> , 2018, 67, 86-96.	7.3	44
166	Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. <i>Liver International</i> , 2011, 31, 676-684.	3.9	43
167	Posttransplantation Hepatitis E. <i>Transplantation</i> , 2013, 96, e4-e6.	1.0	43
168	Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1013-1018.	5.8	43
169	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 719-727.	0.7	41
170	New perspectives for preventing hepatitis C virus liver graft infection. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 735-745.	9.1	41
171	A Critical Review of MELD as a Reliable Tool for Transplant Prioritization. <i>Seminars in Liver Disease</i> , 2019, 39, 403-413.	3.6	41
172	Cardiac Dysautonomia Predicts Long-Term Survival in Hereditary Transthyretin Amyloidosis After Liver Transplantation. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 1432-1441.	5.3	40
173	Prognostic Value and Prediction of Extratumoral Microvascular Invasion for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 2568-2576.	1.5	40
174	Significance of isolated hepatic veno-occlusive disease/sinusoidal obstruction syndrome after liver transplantation. <i>Liver Transplantation</i> , 2011, 17, 798-808.	2.4	39
175	Long-lasting successful dissemination of resistance to oxazolidinones in MDR <i>Staphylococcus epidermidis</i> clinical isolates in a tertiary care hospital in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 41-51.	3.0	39
176	Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1779-1785.	0.7	38
177	Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?. <i>PLoS ONE</i> , 2015, 10, e0138091.	2.5	38
178	Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results. <i>Journal of Hepatology</i> , 2003, 39, 181-189.	3.7	37
179	Human hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein cures fas-induced acute liver failure in mice by attenuating free-radical damage in injured livers. <i>Hepatology</i> , 2011, 53, 618-627.	7.3	37
180	Iodide Transporter NIS Regulates Cancer Cell Motility and Invasiveness by Interacting with the Rho Guanine Nucleotide Exchange Factor LARG. <i>Cancer Research</i> , 2012, 72, 5505-5515.	0.9	37

#	ARTICLE	IF	CITATIONS
181	Persistence of Yellow Fever Vaccine-Induced Antibodies After Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 2458-2461.	4.7	37
182	INFLUENCE OF LIVER HEPATITIS C VIRUS RNA AND HEPATITIS C VIRUS GENOTYPE ON FAS-MEDIATED APOPTOSIS AFTER LIVER TRANSPLANTATION FOR HEPATITIS C. <i>Transplantation</i> , 2000, 70, 1390-1396.	1.0	36
183	Histologic Findings Predictive of a Diagnosis of De novo Autoimmune Hepatitis After Liver Transplantation in Adults. <i>Transplantation</i> , 2013, 96, 670-678.	1.0	36
184	Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation. <i>Hepatology</i> , 2015, 62, 179-187.	7.3	36
185	Alcoholic liver disease: Clinical and translational research. <i>Experimental and Molecular Pathology</i> , 2015, 99, 596-610.	2.1	36
186	Liver transplantation as a rescue therapy for severe neurologic forms of Wilson disease. <i>Neurology</i> , 2020, 94, e2189-e2202.	1.1	36
187	MELD-Na as a prognostic score for cirrhotic patients: Hyponatremia and ascites are back in the game. <i>Journal of Hepatology</i> , 2009, 50, 836-838.	3.7	35
188	Intention-to-treat analysis of percutaneous endovascular treatment of hepatic artery stenosis after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 923-933.	2.4	35
189	Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 957-966.	3.7	35
190	Predicting the risk of post-hepatectomy portal hypertension using a digital twin: A clinical proof of concept. <i>Journal of Hepatology</i> , 2021, 74, 661-669.	3.7	35
191	Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. <i>Hepatology</i> , 2008, 47, 937-948.	7.3	34
192	Spontaneous Splenorenal Shunt in Liver Transplantation. <i>Transplantation</i> , 2015, 99, 2576-2585.	1.0	34
193	Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants. <i>Blood</i> , 2001, 98, 1332-1338.	1.4	33
194	Accuracy of bile duct changes for the diagnosis of chronic liver allograft rejection: Reliability of the 1999 Banff schema. <i>Hepatology</i> , 2002, 35, 117-125.	7.3	33
195	O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. <i>Journal of Hepatology</i> , 2015, 62, S219-S220.	3.7	33
196	Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation. <i>Journal of Hepatology</i> , 1999, 31, 584-592.	3.7	32
197	Hepatitis C, interferon, and risk of rejection after liver transplantation. <i>Liver Transplantation</i> , 2004, 10, 868-871.	2.4	32
198	Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 1367-1378.	2.4	32

#	ARTICLE	IF	CITATIONS
199	Acute Liver Failure/Injury Related to Drug Reaction With Eosinophilia and Systemic Symptoms. <i>Transplantation</i> , 2017, 101, 1830-1837.	1.0	32
200	Combined liver and kidney transplantation in patients with chronic nephritis associated with end-stage liver disease. <i>Nephrology Dialysis Transplantation</i> , 1995, 10, 129-133.	0.7	30
201	Retransplantation of the liver for recurrent hepatitis B virus infection: The Paul Brousse experience. <i>Liver Transplantation</i> , 1999, 5, 166-174.	1.8	30
202	Noninvasive ICG clearance: a useful tool for the management of hepatic artery thrombosis following liver transplantation. <i>Clinical Transplantation</i> , 2011, 25, 297-301.	1.6	30
203	60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC). <i>Journal of Hepatology</i> , 2013, 58, S27.	3.7	30
204	Long-term results of combined liver-kidney transplantation for Primary Hyperoxaluria Type 1: The French experience. <i>Liver Transplantation</i> , 2014, 20, n/a-n/a.	2.4	30
205	Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation. <i>Journal of Hepatology</i> , 2021, 75, S178-S190.	3.7	30
206	47 EFFICACY AND SAFETY OF PROTEASE INHIBITORS FOR SEVERE HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A FIRST MULTICENTRIC EXPERIENCE. <i>Journal of Hepatology</i> , 2012, 56, S21.	3.7	29
207	A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients. <i>Journal of Transplantation</i> , 2012, 2012, 1-9.	0.5	29
208	Hepatitis viruses and liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, S335-S341.	2.8	28
209	Internal Radiotherapy of Liver Cancer with Rat Hepatocarcinoma-Intestine-Pancreas Gene as a Liver Tumor-Specific Promoter. <i>Human Gene Therapy</i> , 2008, 19, 915-926.	2.7	28
210	Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. <i>Liver Transplantation</i> , 2010, 16, 885-894.	2.4	28
211	Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation. <i>Liver Transplantation</i> , 2010, 16, 1136-1146.	2.4	28
212	Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 242-248.	4.4	28
213	Expansion of CMV-Mediated NKG2C+ NK Cells Associates with the Development of Specific De Novo Malignancies in Liver-Transplanted Patients. <i>Journal of Immunology</i> , 2014, 192, 503-511.	0.8	28
214	Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. <i>Aids</i> , 2015, 29, 53-58.	2.2	28
215	SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, S85-S86.	3.7	28
216	Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score. <i>Journal of Hepatology</i> , 2021, 74, 1325-1334.	3.7	28

#	ARTICLE	IF	CITATIONS
217	Recurrence of hepatitis C virus infection after liver transplantation. <i>Journal of Hepatology</i> , 1999, 31, 217-221.	3.7	27
218	Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there. <i>Journal of Hepatology</i> , 2001, 34, 943-945.	3.7	27
219	Identification by Proteomic Tool of Atypical Anti-Liver/Kidney Microsome Autoantibodies Targets in <i>de Novo</i> Autoimmune Hepatitis after Liver Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 345-357.	3.8	27
220	Treatment of recurrent HCV infection following liver transplantation: Results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFN±2a plus ribavirin. <i>Journal of Hepatology</i> , 2012, 57, 564-571.	3.7	27
221	Acute Hepatitis With Periportal Confluent Necrosis Associated With Human Herpesvirus 6 Infection in Liver Transplant Patients. <i>American Journal of Clinical Pathology</i> , 2013, 140, 403-409.	0.7	27
222	Single-Nucleotide Resolution Mapping of Hepatitis B Virus Promoters in Infected Human Livers and Hepatocellular Carcinoma. <i>Journal of Virology</i> , 2016, 90, 10811-10822.	3.4	27
223	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 583-605.	3.7	27
224	Chickenpox-associated fulminant hepatitis that led to liver transplantation in a 63-year-old woman. <i>Liver Transplantation</i> , 2008, 14, 1309-1312.	2.4	26
225	Acute liver failure: Current trends. <i>Journal of Hepatology</i> , 2013, 59, 6-8.	3.7	26
226	Management of <sc>HCV</sc> transplant patients with triple therapy. <i>Liver International</i> , 2014, 34, 46-52.	3.9	26
227	LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*. <i>Journal of Hepatology</i> , 2015, 62, S258-S259.	3.7	26
228	Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies?. <i>Aids</i> , 2014, 28, 1379-1391.	2.2	25
229	Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. <i>Transplantation</i> , 2016, 100, 2129-2137.	1.0	25
230	Hepatitis and solid organ transplantation. <i>Transplantation Proceedings</i> , 2000, 32, 454-457.	0.6	24
231	Sodium Iodide Symporter Is Expressed at the Preneoplastic Stages of Liver Carcinogenesis and in Human Cholangiocarcinoma. <i>Gastroenterology</i> , 2007, 132, 1495-1503.	1.3	24
232	P1319 ONCE-DAILY SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE OR TREATMENT-EXPERIENCED CHRONIC HCV GENOTYPE 4-INFECTED PATIENTS: FINAL RESULTS OF A PHASE III TRIAL. <i>Journal of Hepatology</i> , 2014, 60, S535.	3.7	24
233	Fipexide-induced fulminant hepatitis. <i>Journal of Hepatology</i> , 1992, 15, 144-146.	3.7	23
234	Fulminant Non-A-C Viral Hepatitis Leading to Liver Transplantation. <i>Archives of Internal Medicine</i> , 2000, 160, 388.	3.8	23

#	ARTICLE	IF	CITATIONS
235	Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis?. <i>Clinical Transplantation</i> , 2005, 19, 591-599.	1.6	23
236	A Decision Analysis Model Identifies the Interval of Efficacy for Transarterial Chemoembolization (TACE) in Cirrhotic Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 1328-1332.	1.7	23
237	Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection. <i>Transplantation</i> , 2016, 100, 1507-1512.	1.0	23
238	Occurrence of gammopathies and lymphoproliferative disorders in liver transplant recipients randomized to tacrolimus (FK506)- or cyclosporine-based immunosuppression. <i>Liver Transplantation</i> , 1998, 4, 146-151.	1.8	22
239	Cadaveric full-size liver transplantation and the graft alternatives in adults: A comparative study from a single centre. <i>Journal of Hepatology</i> , 2006, 44, 118-125.	3.7	22
240	Liver transplantation for fulminant hepatitis related to nevirapine therapy. <i>Liver Transplantation</i> , 2006, 12, 1880-1882.	2.4	22
241	Factors associated with nutritional status in liver transplant patients who survived the first year after transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 391-396.	2.8	22
242	Reversibility of Acquired Amyloid Polyneuropathy After Liver Retransplantation. <i>American Journal of Transplantation</i> , 2013, 13, 2734-2738.	4.7	22
243	Quantitative Assessment of Liver Steatosis on Tissue Section Using Infrared Spectroscopy. <i>Gastroenterology</i> , 2015, 148, 295-297.	1.3	22
244	Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals. <i>Liver International</i> , 2015, 35, 44-50.	3.9	22
245	Hepatitis E infection in patients with severe acute alcoholic hepatitis. <i>Liver International</i> , 2015, 35, 870-875.	3.9	22
246	Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. <i>Liver International</i> , 2017, 37, 1869-1876.	3.9	22
247	Respiratory impact of paracentesis in cirrhotic patients with acute lung injury. <i>Journal of Critical Care</i> , 2011, 26, 257-261.	2.2	21
248	Prevention of Hepatitis B Virus Reinfection in Liver Transplant Recipients. <i>Intervirology</i> , 2014, 57, 196-201.	2.8	21
249	Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance. <i>Viruses</i> , 2015, 7, 5155-5168.	3.3	21
250	Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2015, 17, 322-327.	1.7	21
251	Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients. <i>Journal of Hepatology</i> , 1990, 11, 102-110.	3.7	20
252	Prolonged interferon- α therapy of hepatitis B virus-related decompensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 1997, 4, 21-26.	2.0	20

#	ARTICLE	IF	CITATIONS
253	P1232 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY. <i>Journal of Hepatology</i> , 2014, 60, S499.	3.7	20
254	P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials. <i>Journal of Hepatology</i> , 2015, 62, S620-S621.	3.7	20
255	What Should We Expect From a Bioartificial Liver In Fulminant Hepatic Failure?. <i>Artificial Organs</i> , 1998, 22, 26-31.	1.9	19
256	Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. <i>Journal of Viral Hepatitis</i> , 2003, 10, 197-204.	2.0	19
257	Risk factors for hepatocellular carcinoma in Caucasian patients with nonviral cirrhosis: the importance of prior obesity. <i>Liver International</i> , 2015, 35, 1872-1876.	3.9	19
258	Liver Resection for Early Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2020, 272, 820-826.	4.2	19
259	Pneumocystis pneumonia: an opportunistic infection occurring in patients with severe alcoholic hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 26-28.	1.6	18
260	220 PREDICTIVE FACTORS OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH FULMINANT AND SUBFULMINANT HEPATIC FAILURE: RESULTS FROM A RANDOMIZED CONTROLLED MULTICENTER TRIAL. <i>Journal of Hepatology</i> , 2009, 50, S89-S90.	3.7	18
261	Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: Role of an aggressive approach. <i>Liver Transplantation</i> , 2013, 19, 69-77.	2.4	18
262	Randomized Controlled Trial of the NS5A Inhibitor Daclatasvir plus Pegylated Interferon and Ribavirin for HCV Genotype-4 (COMMAND-4). <i>Antiviral Therapy</i> , 2016, 21, 195-205.	1.0	18
263	LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather. <i>Journal of Hepatology</i> , 2015, 62, S278.	3.7	18
264	Optimum timing of treatment for hepatitis C infection relative to liver transplantation. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 165-172.	8.1	18
265	Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation. <i>Transplantation</i> , 2018, 102, 119-126.	1.0	18
266	Management of Fulminant Hepatitis B. <i>Current Infectious Disease Reports</i> , 2019, 21, 25.	3.0	18
267	LIVER TRANSPLANTATION FOR HEPATITIS B. <i>Gastroenterology Clinics of North America</i> , 1993, 22, 271-283.	2.2	18
268	Will transplantation of an hepatitis C infected graft improve the outcome of liver transplantation in HCV patients?. <i>Gastroenterology</i> , 1999, 117, 263-265.	1.3	17
269	Cutaneous thrombotic microangiopathy during treatment with Alpha-interferon for chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 37, 871-872.	3.7	17
270	Fulminant hepatitis after grand mal seizures: Mechanisms and role of liver transplantation. <i>Hepatology</i> , 2003, 38, 443-451.	7.3	17

#	ARTICLE	IF	CITATIONS
271	Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. <i>Transplant International</i> , 2004, 17, 746-758.	1.6	17
272	Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus. <i>Radiology</i> , 2015, 277, 443-453.	7.3	17
273	Autoantibody signatures defined by serological proteome analysis in sera from patients with cholangiocarcinoma. <i>Journal of Translational Medicine</i> , 2016, 14, 17.	4.4	17
274	Approaches for patients with very high MELD scores. <i>JHEP Reports</i> , 2019, 1, 53-65.	4.9	17
275	Liver transplantation in patients with liver failure related to exertional heatstroke. <i>Journal of Hepatology</i> , 2019, 70, 431-439.	3.7	17
276	Liver transplantation in viral hepatitis: Prevention of recurrence. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 1153-1169.	2.4	16
277	Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: A costly strategy for mixed virological results. <i>Journal of Hepatology</i> , 2009, 50, 652-654.	3.7	16
278	Successful Long-term Outcome of ABO-incompatible Liver Transplantation Using Antigen-specific Immunoabsorption Columns. <i>Therapeutic Apheresis and Dialysis</i> , 2010, 14, 116-123.	0.9	16
279	Epstein-Barr Virus Infection and Altered Control of Apoptotic Pathways in Posttransplant Lymphoproliferative Disorders. <i>Pathobiology</i> , 2013, 80, 53-59.	3.8	16
280	Repeat liver retransplantation: rationale and outcomes. <i>Clinical Transplantation</i> , 2016, 30, 312-319.	1.6	16
281	News and challenges in the treatment of hepatitis C in liver transplantation. <i>Liver International</i> , 2016, 36, 34-42.	3.9	16
282	Discrimination of cirrhotic nodules, dysplastic lesions and hepatocellular carcinoma by their vibrational signature. <i>Journal of Translational Medicine</i> , 2016, 14, 9.	4.4	16
283	Evaluation of a micro-spectrometer for the real-time assessment of liver graft with mild-to-moderate macrosteatosis: A proof of concept study. <i>Journal of Hepatology</i> , 2019, 70, 423-430.	3.7	16
284	Rheumatic complications following liver transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 1717-1718.	0.6	15
285	Treatment of patients with hepatic failure: the difficult place of liver support systems. <i>Journal of Hepatology</i> , 2004, 41, 694-695.	3.7	15
286	Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Difficult to manage but essential for success. <i>Journal of Hepatology</i> , 2007, 46, 988-991.	3.7	15
287	Prognosis indicator in acute liver failure: Is there a place for cell death markers?. <i>Journal of Hepatology</i> , 2010, 53, 593-595.	3.7	15
288	Low rejection rates with tacrolimus-based dual and triple regimens following liver transplantation. <i>Clinical Transplantation</i> , 2001, 15, 159-166.	1.6	14

#	ARTICLE	IF	CITATIONS
289	Antiviral treatment of recurrent hepatitis C after liver transplantation: The need for a multifaceted approach. <i>Hepatology</i> , 2005, 41, 436-438.	7.3	14
290	Hepatitis C virus: Up to the minute. <i>Liver Transplantation</i> , 2010, 16, S26-S35.	2.4	14
291	Treatment of Patients with HBV-related Decompensated Cirrhosis and Liver Transplanted Patients. <i>Clinics in Liver Disease</i> , 2013, 17, 451-473.	2.1	14
292	Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus. <i>Transplantation</i> , 2016, 100, 1705-1713.	1.0	14
293	Long-term results of combined kidney and liver transplantation at one center. <i>Transplantation Proceedings</i> , 1997, 29, 2365-2366.	0.6	13
294	Aspects of hepatitis C virus infection relating to liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 313-320.	1.6	13
295	The Reg3 β (HIP/PAP) Lectin Suppresses Extracellular Oxidative Stress in a Murine Model of Acute Liver Failure. <i>PLoS ONE</i> , 2015, 10, e0125584.	2.5	13
296	Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 253-260.	3.0	13
297	Impact of the new MELD-based allocation system on waiting list and post-transplant survival—a cohort analysis using the French national <sc>CRISTAL</sc> database. <i>Transplant International</i> , 2019, 32, 1061-1073.	1.6	13
298	HCV type II has a more pathogenic course after liver transplantation. <i>Hepatology</i> , 1993, 18, A59.	7.3	13
299	No hepatic iron overload 12 years after liver transplantation for hereditary hemochromatosis. <i>Hepatology</i> , 2004, 40, 762-762.	7.3	12
300	New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation?. <i>Transplant Immunology</i> , 2007, 17, 98-107.	1.2	12
301	Domino liver transplantation from familial amyloidotic polyneuropathy donors: how close is the damocles sword to the recipient?. <i>Transplant International</i> , 2007, 20, 921-923.	1.6	12
302	Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. <i>World Journal of Gastroenterology</i> , 2016, 22, 4547.	3.3	12
303	Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. <i>Chest</i> , 2016, 150, 256-258.	0.8	12
304	Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006, 12, 4911.	3.3	12
305	Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen. <i>Journal of Medical Virology</i> , 2001, 65, 493-504.	5.0	11
306	Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. <i>Transplant International</i> , 2004, 17, 759-766.	1.6	11

#	ARTICLE	IF	CITATIONS
307	The questionable role of immunization against hepatitis B in HBV infected liver transplant patients. <i>Journal of Hepatology</i> , 2005, 43, 203-206.	3.7	11
308	The difficulty in timing for liver transplantation in cirrhotic patients coinfectd with HIV: In search for a prognosis score. <i>Liver Transplantation</i> , 2006, 12, 699-701.	2.4	11
309	Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV+HCV coinfectd patients (ANRS-HC08 "THEVICA" trial). <i>Journal of Hepatology</i> , 2009, 51, 1000-1009.	3.7	11
310	The role of corticosteroids in acute-severe autoimmune hepatitis is still highly debatable. <i>Journal of Hepatology</i> , 2015, 63, 1041-1042.	3.7	11
311	Donor HLA Class 1 Evolutionary Divergence Is a Major Predictor of Liver Allograft Rejection. <i>Annals of Internal Medicine</i> , 2021, 174, 1385-1394.	3.9	11
312	Quality of life 10 years after liver transplantation: The impact of graft histology. <i>World Journal of Transplantation</i> , 2016, 6, 703.	1.6	11
313	Antituberculous drugs in patients with chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S408-S412.	2.8	10
314	Place of the liver biopsy in liver transplantation. <i>Journal of Hepatology</i> , 2004, 41, 897-901.	3.7	10
315	The positive financial impact of using an Intensive Care Information System in a tertiary Intensive Care Unit. <i>International Journal of Medical Informatics</i> , 2013, 82, 177-184.	3.3	10
316	1422 END OF TREATMENT RESPONSE AFTER PROTEASE INHIBITOR (PI)- BASED THERAPY FOR HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A MULTICENTRIC EUROPEAN EXPERIENCE. <i>Journal of Hepatology</i> , 2013, 58, S572-S573.	3.7	10
317	<i>Journal of Hepatology</i> , an international top rank journal. <i>Journal of Hepatology</i> , 2014, 60, 3.	3.7	10
318	O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB). <i>Journal of Hepatology</i> , 2015, 62, S251-S252.	3.7	10
319	HCV and HEV recurrence after liver transplantation: one antiviral therapy for two viruses. <i>Transplant International</i> , 2017, 30, 318-319.	1.6	10
320	Prospective validation of transient elastography for staging liver fibrosis in patients undergoing hepatectomy and liver transplantation. <i>Journal of Hepatology</i> , 2018, 68, 199-200.	3.7	10
321	Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. <i>Hepatology</i> , 1995, 21, 333-339.	7.3	10
322	LIVER TRANSPLANTATION FOR FULMINANT HEPATIC FAILURE DUE TO COCAINE INTOXICATION IN AN ALCOHOLIC HEPATITIS C VIRUS-INFECTED PATIENT. <i>Transplantation</i> , 2002, 73, 157.	1.0	10
323	FINE-NEEDLE ASPIRATION BIOPSY OF HUMAN LIVER ALLOGRAFTS. <i>Transplantation</i> , 1990, 50, 704-706.	1.0	9
324	Liver transplantation for hepatitis B virus infection. <i>Liver Transplantation</i> , 1995, 1, 270-274.	1.8	9

#	ARTICLE	IF	CITATIONS
325	Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAM-R) in post liver transplant (post-OLT) patients. Journal of Hepatology, 2002, 36, 32.	3.7	9
326	Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. Transplant International, 2005, 17, 746-58.	1.6	9
327	29 EARLY TRANSPLANTATION IMPROVES SURVIVAL OF NON-RESPONDERS TO CORTICOSTEROIDS IN SEVERE ALCOHOLIC HEPATITIS: A CHALLENGE TO THE 6 MONTH RULE OF ABSTINENCE. Journal of Hepatology, 2010, 52, S13.	3.7	9
328	Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha. Transplant International, 2012, 25, 941-947.	1.6	9
329	Immunoproteomic Analysis of Potentially Severe Non-Graft-Versus-Host Disease Hepatitis After Allogenic Bone Marrow Transplantation. Hepatology, 2013, 57, 689-699.	7.3	9
330	The implementation of an Intensive Care Information System allows shortening the ICU length of stay. Journal of Clinical Monitoring and Computing, 2015, 29, 263-269.	1.6	9
331	Multimodality Imaging of Cardiac Transthyretin Amyloidosis 16 Years After a Domino Liver Transplantation. American Journal of Transplantation, 2016, 16, 2208-2212.	4.7	9
332	Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort. Liver International, 2019, 39, 136-146.	3.9	9
333	Indocyanine Green Fluorescence Imaging to Predict Graft Survival After Orthotopic Liver Transplantation: A Pilot Study. Liver Transplantation, 2020, 26, 1263-1274.	2.4	9
334	Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. Liver International, 2020, 40, 1853-1859.	3.9	9
335	Mortality and long term outcome of combined liver and kidney transplantations. Transplantation Proceedings, 2001, 33, 1179-1180.	0.6	8
336	Liver transplant outcomes in HIV-infected patients. Aids, 2011, 25, 1675-1676.	2.2	8
337	Autoimmune acute liver failure. Hepatology, 2011, 54, 372-372.	7.3	8
338	Natural killer cell deficiency in patients with non-Hodgkin lymphoma after lung transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 604-612.	0.6	8
339	A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases. PLoS ONE, 2016, 11, e0150733.	2.5	8
340	Neuroinflammation in liver disease: sessional talks from ISHEN. Metabolic Brain Disease, 2016, 31, 1339-1354.	2.9	8
341	Spleen volumetry and liver transient elastography: Predictors of persistent posthepatectomy decompensation in patients with hepatocellular carcinoma. Surgery, 2020, 168, 17-24.	1.9	8
342	Liver transplantation in cirrhosis due to hepatitis D virus infection. Journal of Hepatology, 1993, 17, S154-S156.	3.7	7

#	ARTICLE	IF	CITATIONS
343	Experience in one center of combined kidney and liver transplantation in 22 patients: Incidence of graft rejection and long-term graft outcome. <i>Transplantation Proceedings</i> , 1997, 29, 243-244.	0.6	7
344	Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. <i>Clinics in Liver Disease</i> , 2003, 7, 667-681.	2.1	7
345	Extracorporeal liver support with MARS in liver failure: has it a role in the treatment of severe alcoholic hepatitis?. <i>Journal of Hepatology</i> , 2003, 38, 104-106.	3.7	7
346	First year and beyond. <i>Journal of Hepatology</i> , 2011, 54, 3.	3.7	7
347	The Journal of Hepatology: An international journal in a new era. <i>Journal of Hepatology</i> , 2012, 56, 4.	3.7	7
348	Management of post transplant hepatitis C in the direct antiviral agents era. <i>Hepatology International</i> , 2015, 9, 192-201.	4.2	7
349	Treatment and prognosis of acute severe autoimmune hepatitis. <i>Journal of Hepatology</i> , 2017, 66, S4.	3.7	7
350	Immunotherapy in liver transplantation. <i>Journal of Hepatology</i> , 2017, 67, 874-875.	3.7	7
351	Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1682-1689.	3.7	7
352	Morbid obesity increases death and dropout from the liver transplantation waiting list: A prospective cohort study. <i>United European Gastroenterology Journal</i> , 2022, 10, 396-408.	3.8	7
353	Liver transplantation in Italy. Letter to Italian friends. <i>Digestive and Liver Disease</i> , 2002, 34, 619-620.	0.9	6
354	Is early antiviral therapy for recurrent hepatitis C after liver transplantation superior to later treatment? The answer is no. <i>Liver Transplantation</i> , 2011, 17, 488-491.	2.4	6
355	Recombination of hepatitis B virus DNA in patients with HIV. <i>Gut</i> , 2012, 61, 1197-1208.	12.1	6
356	Changing outcomes in acute liver failure: Can we transplant only the ones who really need it?. <i>Liver Transplantation</i> , 2015, 21, S36-S38.	2.4	6
357	Infectious complications after liver transplantation in human immunodeficiency virus-infected recipients. <i>Transplant Infectious Disease</i> , 2015, 17, 662-670.	1.7	6
358	P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation. <i>Journal of Hepatology</i> , 2015, 62, S623.	3.7	6
359	Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study. <i>American Journal of Transplantation</i> , 2017, 17, 2869-2878.	4.7	6
360	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021, 3, 100298.	4.9	6

#	ARTICLE	IF	CITATIONS
361	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 677-689.	2.9	6
362	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. <i>BMC Infectious Diseases</i> , 2022, 22, 94.	2.9	6
363	Assessment of the results of liver transplantation and definition of criteria for the evaluation of transplant centers. <i>Transplantation Proceedings</i> , 1997, 29, 456-458.	0.6	5
364	Tacrolimus (FK506)-Based Dual Versus Triple Therapy Following Liver Transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 1394-1396.	0.6	5
365	Steroid use in HCV-infected liver transplant recipients. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 198-200.	17.8	5
366	Enfuvirtide: A safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 1336-1342.	2.4	5
367	30 ACUTE LIVER FAILURE: CURRENT EUROPEAN PERSPECTIVE. <i>Journal of Hepatology</i> , 2010, 52, S13-S14.	3.7	5
368	Severe fibrosis in patients with recurrent hepatitis C after liver transplantation: A French experience on 250 patients over 15 years (the OrFaire study). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 292-299.	1.5	5
369	Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen: The ANRS CO20-CUPIC study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 443-450.	1.5	5
370	P0600 : Predictive factors of cirrhosis, hepatic decompensation and hepatocellular carcinoma in patients with chronic hepatitis delta. <i>Journal of Hepatology</i> , 2015, 62, S541-S542.	3.7	5
371	P0804 : Efficacy of sofosbuvir-based treatment regimens in HIV/HCV co-infected patients after liver transplantation: The ANRS CO23 CUPILT study. <i>Journal of Hepatology</i> , 2015, 62, S635-S636.	3.7	5
372	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 300.	2.9	5
373	Sofosbuvir+Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. <i>Journal of Viral Hepatitis</i> , 2020, 27, 964-973.	2.0	5
374	Systemic inflammation and liver cirrhosis complications: Driving or secondary event? How to square the circle?. <i>Journal of Hepatology</i> , 2021, 74, 508-510.	3.7	5
375	Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. <i>Hepatology</i> , 1995, 21, 929-932.	7.3	5
376	State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection. <i>Liver International</i> , 2022, 42, 288-298.	3.9	5
377	Liver stiffness-based model predicts hepatic venous pressure gradient in patients with liver disease. <i>Hpb</i> , 2022, 24, 1796-1803.	0.3	5
378	I favor therapy for hepatitis C virus recurrence after transplantation. <i>Liver Transplantation</i> , 2002, 8, S55-S58.	2.4	4

#	ARTICLE	IF	CITATIONS
379	Medical community preferences concerning adult living related donor liver transplantation. Gastroenterologie Clinique Et Biologique, 2006, 30, 183-187.	0.9	4
380	New sensitive tools for hepatitis B virus (HBV) detection in liver transplantation: What will be their impact on the prophylaxis of HBV infection?. Liver Transplantation, 2007, 13, 1084-1087.	2.4	4
381	Combined Prophylaxis Might Still Be Better Than Monoprophylaxis With Entecavir Following Liver Transplantation for Hepatitis B. Gastroenterology, 2012, 142, e34.	1.3	4
382	The international vision of the Journal of Hepatology. Journal of Hepatology, 2013, 58, 3.	3.7	4
383	991 ACUTE LIVER FAILURE IN HIV INFECTED PATIENTS: A SINGLE CENTER EXPERIENCE. Journal of Hepatology, 2013, 58, S409.	3.7	4
384	140 IMPACT OF SARCOPENIA ON MORTALITY AFTER LIVER TRANSPLANTATION IN HIV INFECTED PATIENTS. Journal of Hepatology, 2013, 58, S63.	3.7	4
385	Lengthy Follow-up After Liver Transplantation for Nodular Regenerative Hyperplasia in Human Immunodeficiency Virusâ€“Infected Patients. Transplantation, 2013, 96, e79-e81.	1.0	4
386	Liver metastases from meningeal hemangiopericytoma. Liver International, 2015, 35, 2337-2337.	3.9	4
387	SOF/VEL for 12 Weeks Results in High SVR12 Rates in Subjects with Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy from the Astral-1, Astral-2 and Astral-3 Studies. Journal of Hepatology, 2016, 64, S787-S788.	3.7	4
388	Prevention of decompensation in cirrhosis: a new youth for Î² blockers. Lancet, The, 2019, 393, 1571-1572.	18.7	4
389	Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101459.	1.5	4
390	Prognostic impact of surgical margins for hepatocellular carcinoma according to preoperative alpha-fetoprotein level. Hpb, 2022, 24, 848-856.	0.3	4
391	Cyclin-dependent kinase inhibitors p21 and p27 function as critical regulators of liver regeneration following 90% hepatectomy in the rat. World Journal of Hepatology, 2020, 12, 1198-1210.	2.0	4
392	Liver transplantation in patients with acute liver failure: the European experience. , 1996, , 186-200.		3
393	Treatment of patients with hepatic failure. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, S274-S279.	2.8	3
394	139 Etiology, outcome and early causes of death in 427 patients with acute liver failure (ALF): A 20 year single-center experience. Journal of Hepatology, 2006, 44, S61.	3.7	3
395	[139] POST-ASPIRIN REYE'S SYNDROME IN YOUNG ADULTS: FREQUENT AGGRAVATION OF ENCEPHALOPATHY BY NEUROTROPIC DRUGS AND SPONTANEOUS RECOVERY. Journal of Hepatology, 2007, 46, S63.	3.7	3
396	Prothrombin index slope is an early prognostic marker in patients with severe acute liver diseases: Figure 1. Gut, 2012, 61, 1098-1100.	12.1	3

#	ARTICLE	IF	CITATIONS
397	Role of cytokine levels in assessment of prognosis and post-treatment outcome in hepatocellular carcinoma. <i>Hepatology International</i> , 2013, 7, 788-791.	4.2	3
398	Liver transplantation in the human immunodeficiency virus-hepatitis C virus coinfecting patient: Time to sum up. <i>Hepatology</i> , 2013, 57, 409-411.	7.3	3
399	Liver transplantation for alcoholic hepatitis. Current situation and future. <i>Hepatology International</i> , 2014, 8, 481-485.	4.2	3
400	P508 VALIDATION OF THE CLIF-CONSORTIUM (CLIF-C) SCORE TO PREDICT MORTALITY OF PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) IN AN EXTERNAL COHORT AND FOR SEQUENTIAL MEASUREMENTS. <i>Journal of Hepatology</i> , 2014, 60, S239.	3.7	3
401	Universal Hepatitis B Virus Screening in Patients Receiving Immunosuppressive Therapy: A Small Step for the Oncologists, a Major Advance for Prevention of Hepatitis B Virus Reactivation. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 976-978.	4.4	3
402	Withdrawal of posttransplant hepatitis B virus prophylaxis: A blind test. <i>Liver Transplantation</i> , 2016, 22, 1183-1185.	2.4	3
403	A systematic review of auxiliary liver transplantation of small-for-size grafts in patients with chronic liver disease. <i>JHEP Reports</i> , 2022, 4, 100447.	4.9	3
404	Domino liver transplants for metabolic disorders: Experience with familial amyloidotic polyneuropathy. <i>Journal of Hepatology</i> , 2000, 32, 27.	3.7	2
405	Adoptive transfer of immunity to HBV through liver graft: Does it prevent HBV recurrence?. <i>Hepatology</i> , 2003, 37, 16-18.	7.3	2
406	Bioartificial liver: present and future. <i>Transplantation</i> , 2003, 75, 1769-1770.	1.0	2
407	2 Safety and efficacy of adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B undergoing liver transplantation. <i>Journal of Hepatology</i> , 2006, 44, S3.	3.7	2
408	Liver transplantation in HIV-infected patients. <i>Current Opinion in Organ Transplantation</i> , 2006, 11, 608-612.	1.6	2
409	[628] USE OF LOW-DOSE PEGINTERFERON α -2a (40 kD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: INTERIM RESULTS FROM A RANDOMISED STUDY. <i>Journal of Hepatology</i> , 2007, 46, S237-S238.	3.7	2
410	999 LOW-DOSE PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED, END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: FINAL STUDY RESULTS. <i>Journal of Hepatology</i> , 2008, 48, S374.	3.7	2
411	Are viral or host factors predictive of response to interferon- α ribavirin in transplant patients with hepatitis C?. <i>Journal of Hepatology</i> , 2010, 52, 630-632.	3.7	2
412	Reply to: "Patients with cirrhosis admitted to an Intensive Care Unit". <i>Journal of Hepatology</i> , 2012, 57, 231-232.	3.7	2
413	Transplantation-induced cancers: Emerging evidence that clonal CMV-specific NK cells are causal immunogenic factors. <i>Oncolmmunology</i> , 2014, 3, e28782.	4.6	2
414	P0837 : Efficacy of sofosbuvir and daclatasvir in HIV/HCV co-infected patients with advanced fibrosis. <i>Journal of Hepatology</i> , 2015, 62, S651.	3.7	2

#	ARTICLE	IF	CITATIONS
415	Liver Transplantation in Severe Neurological Forms of Wilson Disease; The French Experience. Journal of Hepatology, 2016, 64, S153.	3.7	2
416	Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study". Journal of Hepatology, 2018, 69, 1397-1398.	3.7	2
417	Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?". Journal of Hepatology, 2018, 69, 550-551.	3.7	2
418	Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference. Journal of Hepatology, 2019, 70, 1297-1300.	3.7	2
419	Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?". Journal of Hepatology, 2019, 70, 566-567.	3.7	2
420	Mild increases in plasma creatinine after intermediate to high-risk abdominal surgery are associated with long-term renal injury. BMC Anesthesiology, 2021, 21, 135.	1.8	2
421	Liver transplantation in HIV-HCV coinfecting patients. New indication and preliminary experience. Journal of Hepatology, 2002, 36, 26-27.	3.7	1
422	Relationship between alcoholic relapse, non compliance and histological lesions after liver transplantation (LT) for alcoholic cirrhosis (AC). Journal of Hepatology, 2002, 36, 38.	3.7	1
423	Adefovir therapy for HBV infection after liver transplantation (LT). Journal of Hepatology, 2002, 36, 42.	3.7	1
424	Transplantation and prevention of reinfection. Current Hepatitis Reports, 2004, 3, 67-75.	0.3	1
425	157 Timing for liver transplantation in HIV coinfecting patients. Journal of Hepatology, 2004, 40, 53.	3.7	1
426	[36] EVOLUTION OF AETIOLOGY AND OUTCOME IN THE LAST 20 YEARS IN 500 PATIENTS WITH ACUTE LIVER FAILURE. FACTORS PREDICTIVE OF SURVIVAL AND OF NEUROLOGICAL SEQUELLAE. Journal of Hepatology, 2007, 46, S17.	3.7	1
427	Molecular tools and hepatocellular carcinoma: Adding help or confusion in liver transplantation?. Journal of Hepatology, 2008, 49, 498-501.	3.7	1
428	71 RISK OF HBV TRANSMISSION IN RECIPIENTS OF LIVER GRAFT FROM HBC ANTIBODY POSITIVE DONORS USING HBIG MONO-PROPHYLAXIS. Journal of Hepatology, 2008, 48, S31.	3.7	1
429	170 VASOPRESSIN-BASED REFLEX REGULATING PORTAL PRESSURE AND BILE HOMEOSTASIS AFTER PARTIAL HEPATECTOMY IN RATS AND HUMANS. Journal of Hepatology, 2008, 48, S73.	3.7	1
430	221 OUTCOME OF CIRRHOTIC PATIENTS ADMITTED TO THE LIVER ICU AND PREDICTIVE FACTORS OF MORTALITY: RESULTS OF A RECENT COHORT OF 308 PATIENTS. Journal of Hepatology, 2009, 50, S90.	3.7	1
431	846 ATP RELEASE AFTER PARTIAL HEPATECTOMY REGULATES LIVER REGENERATION. Journal of Hepatology, 2009, 50, S308.	3.7	1
432	Viral load predicts HBV recurrence after liver transplant. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 657-658.	17.8	1

#	ARTICLE	IF	CITATIONS
433	41 THE SODIUM IODIDE SYMPORTER ENHANCES CELL MIGRATION AND INVASION. <i>Journal of Hepatology</i> , 2010, 52, S18.	3.7	1
434	823 INDETERMINATE CAUSES OF ACUTE LIVER FAILURE: INCIDENCE AND PREDICTIVE FACTORS OF SPONTANEOUS SURVIVAL AND AFTER LIVER TRANSPLANTATION (LT). <i>Journal of Hepatology</i> , 2010, 52, S321.	3.7	1
435	Reply:. <i>Hepatology</i> , 2011, 53, 2138-2139.	7.3	1
436	219 PROSPECTIVE ASSESSMENT OF LIVER FIBROSIS AFTER LIVER TRANSPLANTATION IN HIV/HCV COINFECTED PATIENTS: A USEFUL TOOL ASSESSING SEVERE FIBROSIS ON THE LIVER GRAFT. <i>Journal of Hepatology</i> , 2012, 56, S93.	3.7	1
437	221 20-YEAR PROTOCOL LIVER BIOPSIES: INVASIVE BUT USEFUL FOR THE MANAGEMENT OF LIVER RECIPIENTS. <i>Journal of Hepatology</i> , 2012, 56, S93-S94.	3.7	1
438	976 CENTRILOBULAR CHANGES ARE KEY HISTOLOGICAL FINDINGS FOR SEGREGATING CASES OF DE NOVO AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2012, 56, S381-S382.	3.7	1
439	P1237 ANTI-HEPATITIS C (HCV) TRIPLE THERAPY WITH PROTEASE INHIBITORS IN HIV/HCV CO-INFECTED PATIENTS AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2014, 60, S501.	3.7	1
440	P0579 : Epidemiological, clinical and virological features of hepatitis delta virus infection in France. <i>Journal of Hepatology</i> , 2015, 62, S532-S533.	3.7	1
441	The effect of new HCV drugs on liver transplantation outcomes. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 559-560.	17.8	1
442	Does Multiorgan Failure Impact Prognosis of Liver Transplantation in Patients with End-Stage Liver Disease? Results of a French Retrospective Multicenter Case-Control Study. <i>Journal of Hepatology</i> , 2016, 64, S537.	3.7	1
443	Safety and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir and ± ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3“6). <i>Journal of Hepatology</i> , 2017, 66, S529-S530.	3.7	1
444	Feasibility of anti-HCV direct acting anti-viral agents in French prison settings. <i>Journal of Hepatology</i> , 2017, 66, S743.	3.7	1
445	HCV-positive organ transplants in HCV-negative recipients. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 745-747.	8.1	1
446	Sustained Remission After Treatment Withdrawal in Autoimmune Hepatitis: A Multicenter Retrospective Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2107-2117.	2.3	1
447	Hepatic Arteriovenous Malformation: The Search for a PTEN Mutation!. <i>Hepatology</i> , 2021, 74, 1121-1123.	7.3	1
448	Clinical implications of the quantitation of HCV RNA in liver transplantation. <i>Hepatology</i> , 1993, 18, A71.	7.3	1
449	Mass Spectrometry-Based Proteomics Reveal Alcohol Dehydrogenase 1B as a Blood Biomarker Candidate to Monitor Acetaminophen-Induced Liver Injury. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11071.	4.1	1
450	Transplantation for Viral Hepatitis A and B. , 2005, , 115-128.		1

#	ARTICLE	IF	CITATIONS
451	Impact of COVID " 19 in patients awaiting liver transplantation. Liver International, 2022, 42, 256-257.	3.9	1
452	Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. Journal of Cannabis Research, 2022, 4, .	3.2	1
453	Financial cost analysis of hospital-care treatment of virus C cirrhosis: A multicentric study carried out on 267 consecutively patients in 1998. Gastroenterology, 2000, 118, A1435.	1.3	0
454	The quality of life 10 years after liver transplantation. Journal of Hepatology, 2000, 32, 49.	3.7	0
455	Fulminant viral hepatitis A and B: Different clinical patterns, similar prognosis. Journal of Hepatology, 2000, 32, 54.	3.7	0
456	Risk factors and prognosis of fulminant hepatitis A. Journal of Hepatology, 2000, 32, 106.	3.7	0
457	Sero-lymphotropic copartmentalization of hepatitis C virus quasispecies and severity of liver disease. Journal of Hepatology, 2002, 36, 17.	3.7	0
458	Towards an extension of the indications of liver transplantation (LT) for hepatocellular carcinoma with cirrhosis?. Journal of Hepatology, 2002, 36, 33.	3.7	0
459	Retransplantation of the liver: a reappraisal in the era of combined organ shortage and economical constraints. Journal of Hepatology, 2002, 36, 34.	3.7	0
460	Level of replication and genotypes of hepatitis A virus in fulminant and non-fulminant hepatitis. Journal of Hepatology, 2002, 36, 36.	3.7	0
461	Fulminant hepatitis consecutive to grand mal seizures: mechanisms, role of drugs, of hypoxemia and place of liver transplantation (LT). Journal of Hepatology, 2002, 36, 39.	3.7	0
462	Clinico-pathological, immunological and virological characteristics of patients transplanted for cryptogenic cirrhosis. Journal of Hepatology, 2002, 36, 50.	3.7	0
463	Clinical, biological, genetic characteristics and outcome of patients with severe form of Wilson disease (WD). Journal of Hepatology, 2002, 36, 188-189.	3.7	0
464	Autoimmune liver disease as the main cause of cryptogenic cirrhosis in European patients who underwent liver transplantation. Journal of Hepatology, 2003, 38, 209-210.	3.7	0
465	Domino liver transplantation: A french experience. Journal of Hepatology, 2003, 38, 5.	3.7	0
466	Indeterminate fulminant hepatitis: Clinico-pathological, immunological and virological reevaluation of the pre and post transplantation period of 31 cases transplanted since 1987. Journal of Hepatology, 2003, 38, 41-42.	3.7	0
467	Fatal disseminated kaposi sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Journal of Hepatology, 2003, 38, 48.	3.7	0
468	Long term effect of liver transplantation (LT) on met 30 TTR familial amyloid polyneuropathy (FAP). Journal of Hepatology, 2003, 38, 48.	3.7	0

#	ARTICLE	IF	CITATIONS
469	Pilot study of treatment with pegylated interferon and ribavirin in liver transplant recipients with hepatitis C infection. <i>Journal of Hepatology</i> , 2003, 38, 48-49.	3.7	0
470	140 Influence of graft histologic lesions on recipient quality of life 10 years after liver transplantation. <i>Journal of Hepatology</i> , 2004, 40, 48-49.	3.7	0
471	160 Severe primary HHV8 infection following transplantation with anti-HHV8-positive liver grafts. <i>Journal of Hepatology</i> , 2004, 40, 54.	3.7	0
472	265 HBV recurrence associated with HCC recurrence after liver transplantation: Role of HBV production from tumoral cells. <i>Journal of Hepatology</i> , 2004, 40, 83.	3.7	0
473	473 Compartmentalization of hepatitis C virus and response to therapy. <i>Journal of Hepatology</i> , 2004, 40, 140.	3.7	0
474	Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. <i>Transplant International</i> , 2005, , .	1.6	0
475	161 Albumin dialysis using the MARS® system in the treatment of patients with end-stage liver disease and renal failure. <i>Journal of Hepatology</i> , 2006, 44, S68.	3.7	0
476	245 Comparative proteomic analysis of hepatocellular carcinomas on non-fibrotic liver and hepatocellular adenomas. <i>Journal of Hepatology</i> , 2006, 44, S98.	3.7	0
477	629 Identification of new autoantigens on liver plasma membranes in type 1 autoimmune hepatitis by proteome analysis. <i>Journal of Hepatology</i> , 2006, 44, S233-S234.	3.7	0
478	[154] SURVIVAL ANALYSIS OF HIV INFECTED PATIENTS REFERRED TO A LIVER TRANSPLANT UNIT. <i>Journal of Hepatology</i> , 2007, 46, S68.	3.7	0
479	[175] SPECIFIC ANTI-HCV IMMUNE RESPONSES AFTER LIVER TRANSPLANTATION IN HIV/HCV CO-INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2007, 46, S75.	3.7	0
480	191 EVOLUTION AFTER LISTING AND RESULTS OF LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA IN HIV/HCV AND HIV/HBV COINFECTED PATIENTS. <i>Journal of Hepatology</i> , 2008, 48, S80-S81.	3.7	0
481	233 EFFECT OF ANTIVIRAL TREATMENT, RETREATMENT, AND STAGE OF FIBROSIS ON PROGRESSION OF LIVER FIBROSIS, AND OUTCOME AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2008, 48, S95-S96.	3.7	0
482	423 HCV CORE TUMOR VARIANTS SHIFT TGF-BETA RESPONSES FROM TUMOR SUPPRESSION TO ONCOGENESIS IN PRIMARY HUMAN AND MOUSE HEPATOCYTES. <i>Journal of Hepatology</i> , 2008, 48, S163.	3.7	0
483	542 INTERNAL RADIOTHERAPY OF LIVER CANCER USING RAT HEPATOCARCINOMA-INTESTINE-PANCREAS GENE AS A LIVER TUMOR-SPECIFIC PROMOTER. <i>Journal of Hepatology</i> , 2008, 48, S203-S204.	3.7	0
484	860 HNRNP A2/B1 AS ANTINUCLEAR ANTIBODIES TARGET: EPITOPE MAPPING AND DIFFERENTIAL REACTIVITY IN AUTOIMMUNE HEPATITIS AND CONNECTIVE TISSUE DISEASES. <i>Journal of Hepatology</i> , 2008, 48, S323.	3.7	0
485	237 HCV CORE-DEPENDENT DECREASE OF SMAD3 ACTIVATION PROMOTES TGF- β -INDUCED EPITHELIAL MESENCHYMAL TRANSITION. <i>Journal of Hepatology</i> , 2009, 50, S96.	3.7	0
486	398 HUMORAL NEUTRALIZING RESPONSE TO HCV DURING HIV COINFECTION AND LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2009, 50, S151.	3.7	0

#	ARTICLE	IF	CITATIONS
487	443 PROGNOSIS OF SEVERE RECURRENCE OF HCV INFECTION AFTER LIVER TRANSPLANTATION IN A LARGE COHORT OF HIV INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2009, 50, S168.	3.7	0
488	459 ANALYSE OF PREDICTIVE FACTORS OF MORTALITY OF HIV/HCV INFECTED PATIENTS ON THE WAITING LIST OF LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2009, 50, S173.	3.7	0
489	EFFICACY AND LONG-TERM OUTCOME OF AMPHOTERICIN B LIPID COMPLEX (ABLC) PROPHYLAXIS IN HIGH RISK LIVER TRANSPLANT RECIPIENTS IN THE CURRENT PRACTICE. <i>Transplantation</i> , 2010, 90, 116.	1.0	0
490	RISK ASSESSMENT OF LIVER DONATION FOR PATIENTS WITH FAMILIAL AMYLOID POLYNEUROPATHY IN DOMINO LIVER TRANSPLANTATION: 100 CASES FROM A SINGLE CENTER. <i>Transplantation</i> , 2010, 90, 449.	1.0	0
491	1095 DEMONSTRATION OF AN HEPATOCYTE CANALICULAR LOCALIZATION OF CYP2D6, THE TARGET OF LIVER KIDNEY MICROSOME TYPE 1 AUTOANTIBODIES, MARKERS OF TYPE 2 AUTOIMMUNE HEPATITIS. <i>Journal of Hepatology</i> , 2010, 52, S423.	3.7	0
492	Focus. <i>Journal of Hepatology</i> , 2010, 52, 3-4.	3.7	0
493	464 CHARACTERISTICS AND PROGNOSIS OF FIBROSING CHOLESTATIC HEPATITIS AFTER LIVER TRANSPLANTATION IN A LARGE COHORT OF HIV/HCV CO-INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S188.	3.7	0
494	465 LONG TERM RESULTS OF LIVER TRANSPLANTATION FOR WILSON'S DISEASE (WD): THE FRENCH EXPERIENCE. <i>Journal of Hepatology</i> , 2010, 52, S188-S189.	3.7	0
495	493 RESULTS OF LIVER RETRANSPLANTATION IN A MONOCENTRIC COHORT OF HCV INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S199.	3.7	0
496	495 ARE LIVER TRANSPLANT HIV-1 INFECTED PATIENTS AT RISK TO DEVELOP HIV-1 DRUG RESISTANCE?. <i>Journal of Hepatology</i> , 2010, 52, S199-S200.	3.7	0
497	866 IDENTIFICATION OF NOVEL CELLULAR TARGETS IN HUMAN INTRAHEPATIC CHOLANGIOCARCINOMA USING LASER MICRODISSECTION AND AMT-TAG PROTEOMICS. <i>Journal of Hepatology</i> , 2010, 52, S337.	3.7	0
498	929 ANTI-OXIDANT CURATIVE EFFECT OF A MANUFACTURED HIP/PAP PROTEIN AGAINST FULMINANT HEPATITIS. <i>Journal of Hepatology</i> , 2010, 52, S360.	3.7	0
499	1041 HCV CORE PROTEIN INDUCES INTRAHEPATIC TGF-BETA ACTIVATION IN TRANSGENIC MICE. <i>Journal of Hepatology</i> , 2010, 52, S403.	3.7	0
500	1313 AUTOANTIGEN IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS IN PATIENTS WITH A NEW TYPE OF AUTOIMMUNE-LIKE HEPATITIS OCCURRING AFTER BONE MARROW TRANSPLANTATION. <i>Journal of Hepatology</i> , 2011, 54, S517-S518.	3.7	0
501	765 HCV CORE PROTEIN MODULATES TGF- β RESPONSES IN AN AUTOCRINE AND PARACRINE MANNER, A NOVEL PARADIGM FOR THE INTERPLAY BETWEEN HOST- AND VIRAL-RELATED CARCINOGENETIC SIGNALS. <i>Journal of Hepatology</i> , 2011, 54, S308.	3.7	0
502	190 DE NOVO AUTO-IMMUNE HEPATITIS AND HCV RECURRENCE AFTER LIVER TRANSPLANTATION: A CHALLENGING DIAGNOSIS AND POOR PROGNOSIS. <i>Journal of Hepatology</i> , 2012, 56, S82.	3.7	0
503	209 SYSTEMATIC CT-SCAN ON POST-OPERATIVE DAY 7 AFTER LIVER TRANSPLANTATION DECREASES THE RATE OF RETRANSPLANTATION FOR ARTERIAL COMPLICATIONS. <i>Journal of Hepatology</i> , 2012, 56, S89.	3.7	0
504	255 GAMMA SMOOTH MUSCLE ACTIN: AN EPITHELIAL MESENCHYMAL TRANSITION MARKER IN HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2012, 56, S107.	3.7	0

#	ARTICLE	IF	CITATIONS
505	688 RISK FACTORS FOR HEPATOCELLULAR CARCINOMA OR LIVER FAILURE IN CAUCASIANS PATIENTS WITH NON-VIRAL CIRRHOSIS: THE IMPORTANCE OF PAST OVERWEIGHT. <i>Journal of Hepatology</i> , 2012, 56, S273.	3.7	0
506	840 SEPTIN 9 REGULATES LIPID DROPLETS ACCUMULATION AND HEPATITIS C VIRUS REPLICATION IN A SUMO1 DEPENDENT PROCESS. <i>Journal of Hepatology</i> , 2012, 56, S328.	3.7	0
507	937 AUTOIMMUNE-LIKE HEPATITIS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION: A NEW ENTITY CHARACTERISED BY USING A PROTEOMIC APPROACH. <i>Journal of Hepatology</i> , 2012, 56, S366.	3.7	0
508	1031 PROGNOSTIC FACTORS AT TEN YEARS AFTER LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2012, 56, S403.	3.7	0
509	1070 DISCRIMINATING CIRRHOSIS AND HEPATOCELLULAR CARCINOMA BY IN SITU CHEMICAL ANALYSIS USING INFRARED MICROSPECTROSCOPY. <i>Journal of Hepatology</i> , 2013, 58, S438-S439.	3.7	0
510	170 IMPACT OF ADJUVANT CHEMOTHERAPY FOR HEPATOCELLULAR CARCINOMA BEYOND MILAN ON HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2013, 58, S75-S76.	3.7	0
511	1042 HEPATOCELLULAR CARCINOMA REPLICATING HEPATITIS B VIRUS HAVE TRANSCRIPTOMIC, HISTOLOGICAL AND CLINICAL CHARACTERISTICS. <i>Journal of Hepatology</i> , 2013, 58, S428.	3.7	0
512	184 PREDICTIVE FACTORS OF SURVIVAL AND PROGNOSTIC SCORE VALIDATION IN LIVER RETRANSPLANTATION FOR SEVERE HEPATITIS C RECURRENCE: THE IMPORTANCE OF HCV THERAPY BEFORE AND AFTER RETRANSPLANTATION. <i>Journal of Hepatology</i> , 2013, 58, S81.	3.7	0
513	997 FULMINANT HEPATITIS LISTED FOR EMERGENCY LIVER TRANSPLANTATION IN FRANCE – EPIDEMIOLOGY AND OUTCOME. <i>Journal of Hepatology</i> , 2013, 58, S411.	3.7	0
514	Postliver Transplantation Pulmonary Complications. <i>Transplantation</i> , 2013, 95, e43-e44.	1.0	0
515	Optimal Management of HCV Transplant Patients. <i>Current Hepatology Reports</i> , 2014, 13, 304-313.	0.9	0
516	P334 AN INFLAMMATORY EXTRACELLULAR MATRIX IS A MOLECULAR TARGET OF THE ROS SCAVENGER HIP/PAP. <i>Journal of Hepatology</i> , 2014, 60, S178.	3.7	0
517	P1111 ANRS HC15 NRFI: LONG-TERM MAINTENANCE THERAPY WITH A COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON IN CHRONIC HEPATITIS C. RESULTS OF A MULTICENTER RANDOMIZED CONTROLLED TRIAL. <i>Journal of Hepatology</i> , 2014, 60, S448-S449.	3.7	0
518	P455 BACTERIAL ENDOCARDITIS IN PATIENTS WITH CIRRHOSIS: A MULTICENTER RETROSPECTIVE STUDY OF 78 CASES. <i>Journal of Hepatology</i> , 2014, 60, S220-S221.	3.7	0
519	P910 IMPACT OF ANEMIA IN VIRAL RESPONSE DURING TRIPLE THERAPY IN LIVER TRANSPLANT RECIPIENTS. <i>Journal of Hepatology</i> , 2014, 60, S378.	3.7	0
520	O49 SEPTIN 9 BINDS PtdIns4P AND REGULATES LIPID DROPLETS DISTRIBUTION IN HCV INFECTED CELLS. <i>Journal of Hepatology</i> , 2014, 60, S20.	3.7	0
521	P694 HEPATITIS E INFECTION IN PATIENTS WITH SEVERE ACUTE ALCOHOLIC HEPATITIS. <i>Journal of Hepatology</i> , 2014, 60, S300.	3.7	0
522	Five exciting years at the <i>Journal of Hepatology</i> – An open road to the future. <i>Journal of Hepatology</i> , 2014, 61, 1193-1195.	3.7	0

#	ARTICLE	IF	CITATIONS
523	P0034 : Good outcome of patients transplanted with meld score greater than 30: Paul-brousse hospital experience. Journal of Hepatology, 2015, 62, S304.	3.7	0
524	P0137 : Safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation. Analysis from a French multicenter, open-label study (ANRS HC29 bocepretransplant). Journal of Hepatology, 2015, 62, S352-S353.	3.7	0
525	P0150 : Liver cirrhosis is independently associated with mortality in patients with bacterial endocarditis: Results of a case control multicenter study of 202 cases. Journal of Hepatology, 2015, 62, S358.	3.7	0
526	LP19 : Early introduction of subcutaneous (S.C.) hepatitis B immunoglobulin (HBIG) provides effective prophylaxis for hepatitis B virus (HBV) reinfection after liver transplantation (TX). Journal of Hepatology, 2015, 62, S273.	3.7	0
527	P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic. Journal of Hepatology, 2015, 62, S617-S618.	3.7	0
528	Prevention of Post-transplant HBV. Current Hepatology Reports, 2015, 14, 153-163.	0.9	0
529	Transplantation for Hepatitis A and B. , 2015, , 105-119.		0
530	P1107 : Unconsidered misuse of acetaminophen is one of the causal cofactors of acute liver failure in adults with severe dengue fever. Journal of Hepatology, 2015, 62, S765.	3.7	0
531	Are the Early Quality of Life Benefits Sustained Long-Term after Liver Transplantation? a 10-Year Longitudinal Diagnosis Stratified Evaluation. Journal of Hepatology, 2016, 64, S552-S553.	3.7	0
532	Dynamic outcome prediction for paracetamol-related acute liver failure. The Lancet Gastroenterology and Hepatology, 2016, 1, 177-178.	8.1	0
533	Comparative antiviral efficacy with higher ALT normalization of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in HBeAg-negative, genotype D chronic hepatitis B. Digestive and Liver Disease, 2017, 49, e63.	0.9	0
534	Apico-basal polarity in epithelial cell morphogenesis and liver pathogenesis. Journal of Hepatology, 2017, 66, S317.	3.7	0
535	Factors associated with tumor recurrence after liver transplantation for hepatocellular carcinoma: prospective cohort on 371 patients. Journal of Hepatology, 2017, 66, S200.	3.7	0
536	Cutting out the roots of acute hepatitis C. Lancet Infectious Diseases, The, 2017, 17, 125-127.	9.1	0
537	Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT). Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 56-65.	1.5	0
538	Prognosis of ALF of unknown cause: results of the French multicentre prospective HASIPRO study. Journal of Hepatology, 2018, 68, S68-S69.	3.7	0
539	Reply to: "Mortality due to immunotherapy related hepatitis". Journal of Hepatology, 2018, 69, 978-979.	3.7	0
540	Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. European Journal of Clinical Pharmacology, 2019, 75, 1555-1563.	1.9	0

#	ARTICLE	IF	CITATIONS
541	Comparative analysis of outcomes after liver resection and liver transplantation for early stages hepatocellular carcinoma in HIV-infected patients. An intention-to-treat analysis. Hpb, 2020, 22, 900-910.	0.3	0
542	Management of Transplant Patients Infected with HCV. , 2021, , 153-173.		0
543	Hepatitis C and Liver Transplantation in the HIV Co-infected Patients. , 2014, , 65-76.		0
544	Hepatitis B Recurrence: Major Milestones and Current Status. , 2016, , 13-34.		0